OR WAIT null SECS
The company believes the investment will improve its support of clients’ research, development, and clinical manufacturing needs by expanding its development and manufacturing capacity.
Upperton Pharma Solutions, a contract development and manufacturing organization (CDMO) based in the United Kingdom, announced its investment into the O Hara LC M5 tablet coater to increase its solid dosage form capabilities. The company believes the investment will improve its support of clients’ research, development, and clinical manufacturing needs by expanding its development and manufacturing capacity, according to an Oct. 29, 2019 press release.
The new tablet coater comes equipped with a range of interchangeable pans to support projects from R&D coating studies through to production of clinical batches, according to the release. The device uses the same technology as larger-scale equipment, which de-risks the scale-up process.
“Upperton [is] committed to expanding its GMP processing capabilities and we have seen acquisitions in rotary compressing capability and now tablet coating,” said Paul Kelsall, director of Clinical Manufacture, Upperton, in the press release. “These are significant advances in our service offering and enables us to meet our [clients’] requirements beyond our core capability of spray drying. The O'Hara LC M5 coater will be a critical part of our service offering and will give us great flexibility in the coating operation.”
“The acquisition of flexible capsule and tablet coating capabilities is yet another important piece of the jigsaw in our expansion program,” added Dr. Richard Johnson, founder and CEO, Upperton, in the press release. “The addition of the LC M5 coater to our range of capabilities demonstrates to our customers our ambition to acquire the most up-to-date formulation technologies that the industry has to offer.”
Upperton will be showcasing its services from Nov. 5–7 at stand 41H20 at CPhI Worldwide in Frankfurt, Germany.